Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

32.55
-0.3131-0.95%
Post-market: 32.55-0.0070-0.02%17:07 EDT
Volume:432
Turnover:14.10K
Market Cap:6.51M
PE:- -
High:32.56
Open:32.56
Low:32.55
Close:32.87
52wk High:43.01
52wk Low:27.40
Shares:200.00K
Float Shares:200.00K
Volume Ratio:0.31
T/O Rate:0.22%
Dividend:0.32
Dividend Rate:0.98%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)

TIPRANKS
·
Sep 16

Scholar Rock says FDA requested pregnancy safety study for Isembyld

TIPRANKS
·
Sep 16

Scholar Rock Shares Fall After Barclays Downgrade

MT Newswires Live
·
Sep 16

Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

MT Newswires Live
·
Sep 16

Scholar Rock Holding Price Target Raised to $70.00/Share from $64.00 by Wedbush

Dow Jones
·
Sep 15

Scholar Rock Holding Corporation : H.c. Wainwright Raises Target Price to $70 from $65

THOMSON REUTERS
·
Sep 15

Brain-Computer Breakthrough Enables Paralysed Individuals to Communicate Through Digital Avatars

Deep News
·
Sep 15

Market Playbook: Key Bullish and Bearish Signals for Stocks on September 15, 2026

Deep News
·
Sep 15

Scholar Rock downgraded to Equal Weight from Overweight at Barclays

TIPRANKS
·
Sep 15

Kestra Medical Technologies Q1 Revenue Beats Estimates, Raises FY Revenue Outlook

Reuters
·
Sep 15

Scholar Rock Says Its First Muscle-Targeted SMA Therapy Will Cost About $310,000 Annually

Reuters
·
Sep 14

Scholar Rock Holding Price Target Maintained with a $64.00/Share by Wedbush

Dow Jones
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

Scholar Rock Exec Says Its First Drug to Target Muscle Loss in Spinal Mus­Cu­Lar at­Ro­Phy Has a Wholesale Acquisition Cost of $11,659 for a Single Use Vial - Conf.call

THOMSON REUTERS
·
Sep 14

Scholar Rock Exec Says Co Expects the Annual Net Cost in the U.S. for a Typical Patient to be Approximately $310,000

THOMSON REUTERS
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14

Top Premarket Gainers

MT Newswires Live
·
Sep 14

Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating

MT Newswires Live
·
Sep 14

Scholar Rock Shares up 11.6% Premarket After FDA Nod for First Muscle-Targeted Drug for Type of Genetic Disease

THOMSON REUTERS
·
Sep 14

Scholar Rock Holding Corporation : Citigroup Raises Target Price to $74 from $60

THOMSON REUTERS
·
Sep 14